AstraZeneca have announced that Axanum, a fixed dose combination of 81 mg low-dose ASA (acetylsalicylic acid) and 20 mg esomeprazole, has received positive agreement for approval in 23 European Union member countries and in Norway. The combination is indicated for prevention of cardiovascular events such as heart attack or stroke, in high-risk patients in need of
US-based biopharmaceutical services company Quintiles is expanding its remit in Russia by launching its first commercial project in the market. The project involves a 40-strong sales team and comes after Quintiles set up a local legal entity to deliver commercial operations in the country and appointed Sergey Smirnov as head of business development & operations,
Clinical Professionals continues to see an increase in group numbers for our European focused groups. We now have a number of groups based in European locations to assist candidates looking for employment. Below you will find the complete list of groups we manage, please feel free to join relevant groups and join the discussions/news etc
Bristol-Myers Squibb has hit the acquisition trail again and is buying privately held Amira Pharmaceuticals in a deal that could be worth $475 million to the inflammatory and fibrotic diseases specialist. Under the terms of the agreement, B-MS is shelling out $325 million in an upfront fee and may make additional milestone payments totalling $150
Roche has signed an agreement to acquire mtm laboratories, a privately-held German in vitro diagnostics company which specialises in early detection of cervical cancer. Under the terms of the deal, the Swiss major will pay shareholders in the Heidelberg-based group an upfront payment of around 130 million euros, plus an extra 60 million euros “upon
ICON has expanded its capacity to drive study quality and efficacy in clinical research by acquiring fellow Irish company Firecrest Clinical. No financial details were released on the deal. Founded in 2001 and based in Limerick, Firecrest has developed and markets a site-performance management system that ICON says has been used by nine of the
GlaxoSmithKline (GSK) has entered into an agreement to purchase Shenzhen Neptunus’ stake in a previously formed joint venture between the companies involved in the development and manufacture of influenza vaccines in China, Hong Kong, and Macau. GSK will pay Shenzhen Neptunus $39 million, after which GSK will be the sole owner of the joint venture
Amgen has been boosted by the news that regulators in the European Union have given the green light to Xgeva for cancer-related fractures.
Amgen has been boosted by the news that regulators in the European Union have given the green light to Xgeva for cancer-related fractures. Specifically, the European Commission has granted marketing authorisation for Xgeva (denosumab) for the prevention of skeletal-related events in adults with bone metastases from solid tumours. The Commission has also granted the drug
Quintiles is considering setting up at least two more Prime Sites in the UK to make the most of what it regards as a still fertile environment for clinical trials. The US-based biopharmaceutical services company established the first of its international network of Prime Sites at Queen Mary, University of London in 2007. The company recently gave a further vote of confidence to the UK as a key location for clinical research by investing in a clinical research facility – part of the new William Harvey Heart Centre – at the same site.
As part of our continued expansion, Clinical Professionals now advertise all UK and European roles on New Scientist. New Scientist is a weekly international science magazine and website covering recent developments in science and technology for a general English-speaking audience. Founded in 1956, it is published by Reed Business Information Ltd and based in London.